Iatrogenic Withdrawal Syndrome in Critically Ill Neonates: A Review of Mechanisms, Assessment, Management, and Prevention

Abstract

Considering that neonatal pain is a relevant matter given its implications and consequences, many neonates, particularly those undergoing critical care, are subjected to analgo-sedation therapies, which commonly includes treatment with opioids and benzodiazepines. These drugs, however, can induce tolerance and dependency, leading to the development of the so-called iatrogenic withdrawal syndrome (IWS) which is observed following discontinuation of these therapeutic agents particularly when utilized for a prolonged period of time (≥5 days). IWS consists of signs and symptoms manifested especially in young children, such as term and premature newborns in the neonatal intensive care unit, who are less capable of metabolizing and eliminating these drugs, compared with older patients. In this study, we review assessment tools that were developed to identify, evaluate, and manage children affected by IWS. The studies reviewed demonstrate that optimal management of IWS includes consideration of alternate routes of drug administration, the need for adequate time for drug tapering, and also the presence of planned rescue therapy when encountering cases refractory to ongoing management. Equally important is prevention of IWS which can be accomplished with the implementation of drug rotation protocols and, adherence to evidenced-based guidelines which facilitate an overall decline in the use and duration of opioids and benzodiazepines. Finally, our review strongly supports the need for more research on IWS in neonates given their increased susceptibility and sparse published data for this age group.

Keywords

analgo-sedation - benzodiazepine - neonatal - opioid - withdrawal

Publikationsverlauf

Eingereicht: 29. Juni 2022

Angenommen: 01. Oktober 2022

Artikel online veröffentlicht:
01. Dezember 2022

• References

• 1 Fitri SYR, Lusmilasari L, Juffrie M, Rakhmawati W. Pain in neonates: a concept analysis. Anesth Pain Med 2019; 9 (04) e92455
• 2 Walker SM. Neonatal pain. Paediatr Anaesth 2014; 24 (01) 39-48
• 3 Walker SM. Long-term effects of neonatal pain. Semin Fetal Neonatal Med 2019; 24 (04) 101005
• 4 Carter BS, Brunkhorst J. Neonatal pain management. Semin Perinatol 2017; 41 (02) 111-116
• 5 Valeri BO, Holsti L, Linhares MBM. Neonatal pain and developmental outcomes in children born preterm: a systematic review. Clin J Pain 2015; 31 (04) 355-362
• 6 Smits A, van den Anker JN, Allegaert K. Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use. J Pharm Pharmacol 2017; 69 (04) 350-360
• 7 LaRosa JM, Aponte-Patel L. Iatrogenic withdrawal syndrome: a review of pathophysiology, prevention, and treatment. Curr Pediatr Rep 2019; 7 (01) 12-19
• 8 Harris J, Ramelet AS, van Dijk M. et al. Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals. Intensive Care Med 2016; 42 (06) 972-986
• 9 Isaac L, van den Hoogen NJ, Habib S, Trang T. Maternal and iatrogenic neonatal opioid withdrawal syndrome: differences and similarities in recognition, management, and consequences. J Neurosci Res 2022; 100 (01) 373-395
• 10 Ávila-Alzate JA, Gómez-Salgado J, Romero-Martín M, Martínez-Isasi S, Navarro-Abal Y, Fernández-García D. Assessment and treatment of the withdrawal syndrome in paediatric intensive care units: systematic review. Medicine (Baltimore) 2020; 99 (05) e18502
• 11 Duceppe MA, Perreault MM, Frenette AJ. et al. Frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and benzodiazepines in critically Ill neonates, children and adults: a systematic review of clinical studies. J Clin Pharm Ther 2019; 44 (02) 148-156
• 12 Best KM, Boullata JI, Curley MAQ. Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model. Pediatr Crit Care Med 2015; 16 (02) 175-183
• 13 Pergolizzi Jr JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther 2020; 45 (05) 892-903
• 14 Donato J, Rao K, Lewis T. Pharmacology of common analgesic and sedative drugs used in the neonatal intensive care unit. Clin Perinatol 2019; 46 (04) 673-692
• 15 Thigpen JC, Odle BL, Harirforoosh S. Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. Eur J Drug Metab Pharmacokinet 2019; 44 (05) 591-609
• 16 Fenn III NE, Plake KS. Opioid and benzodiazepine weaning in pediatric patients: review of current literature. Pharmacotherapy 2017; 37 (11) 1458-1468
• 17 Griffin III CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013; 13 (02) 214-223
• 18 Gravielle MC. Regulation of GABA_A receptors by prolonged exposure to endogenous and exogenous ligands. Neurochem Int 2018; 118: 96-104
• 19 Jacqz-Aigrain E, Burtin P. Clinical pharmacokinetics of sedatives in neonates. Clin Pharmacokinet 1996; 31 (06) 423-443
• 20 Franck LS, Naughton I, Winter I. Opioid and benzodiazepine withdrawal symptoms in paediatric intensive care patients. Intensive Crit Care Nurs 2004; 20 (06) 344-351
• 21 Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MAQ. The withdrawal assessment tool - version 1 (WAT-1). Pediatr Crit Care Med J 2008; 9 (06) 573-580
• 22 Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the withdrawal assessment tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012; 153 (01) 142-148
• 23 Dokken M, Rustøen T, Diep LM. et al. Iatrogenic withdrawal syndrome frequently occurs in paediatric intensive care without algorithm for tapering of analgosedation. Acta Anaesthesiol Scand 2021; 65 (07) 928-935
• 24 Ista E, van Dijk M, de Hoog M, Tibboel D, Duivenvoorden HJ. Construction of the Sophia Observation withdrawal Symptoms-scale (SOS) for critically ill children. Intensive Care Med 2009; 35 (06) 1075-1081
• 25 Ista E, van Dijk M, Gamel C, Tibboel D, de Hoog M. Withdrawal symptoms in children after long-term administration of sedatives and/or analgesics: a literature review. “Assessment remains troublesome”. Intensive Care Med 2007; 33 (08) 1396-1406
• 26 Ista E, de Hoog M, Tibboel D, Duivenvoorden HJ, van Dijk M. Psychometric evaluation of the Sophia Observation withdrawal symptoms scale in critically ill children. Pediatr Crit Care Med 2013; 14 (08) 761-769
• 27 Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol Biopharm 1975; 12 (1-2): 19-32
• 28 Smith HAB, Besunder JB, Betters KA. et al. 2022 Society of Critical Care Medicine Clinical Practice Guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. Pediatr Crit Care Med 2022; 23 (02) e74-e110
• 29 D'Souza G, Wren AA, Almgren C, Ross AC, Marshall A, Golianu B. Pharmacological strategies for decreasing opioid therapy and management of side effects from chronic use. Children (Basel) 2018; 5 (12) 163
• 30 Dervan LA, Yaghmai B, Watson RS, Wolf FM. The use of methadone to facilitate opioid weaning in pediatric critical care patients: a systematic review of the literature and meta-analysis. Paediatr Anaesth 2017; 27 (03) 228-239
• 31 McPherson C, Ortinau CM, Vesoulis Z. Practical approaches to sedation and analgesia in the newborn. J Perinatol 2021; 41 (03) 383-395
• 32 Haenecour AS, Seto W, Urbain CM, Stephens D, Laussen PC, Balit CR. Prolonged dexmedetomidine infusion and drug withdrawal in critically ill children. J Pediatr Pharmacol Ther 2017; 22 (06) 453-460
• 33 Mondardini MC, Sperotto F, Daverio M. et al. Efficacy and safety of dexmedetomidine for prevention of withdrawal syndrome in the pediatric intensive care unit: protocol for an adaptive, multicenter, randomized, double-blind, placebo-controlled, non-profit clinical trial. Trials 2019; 20 (01) 710
• 34 Sanavia E, Mencía S, Lafever SN, Solana MJ, Garcia M, López-Herce J. Sedative and analgesic drug rotation protocol in critically ill children with prolonged sedation: evaluation of implementation and efficacy to reduce withdrawal syndrome. Pediatr Crit Care Med 2019; 20 (12) 1111-1117
• 35 Rana D, Bellflower B, Sahni J. et al. Reduced narcotic and sedative utilization in a NICU after implementation of pain management guidelines. J Perinatol 2017; 37 (09) 1038-1042
• 36 Craske J, Carter B, Jarman I, Tume L. Parent's experiences of their child's withdrawal syndrome: a driver for reciprocal nurse-parent partnership in withdrawal assessment. Intensive Crit Care Nurs 2019; 50: 71-78
• 37 Salekin MS, Mouton PR, Zamzmi G. et al. Future roles of artificial intelligence in early pain management of newborns. Paediatr Neonatal Pain 2021; 3 (03) 134-145